Skip to main content

cael-101

Generic: anselamimab

cael-101: 2 clinical trials tracked.

cael-101 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about cael-101, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

AL Amyloidosis
Clinical Trial Registry Records (2)

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL Amyloidosis

NCT04512235Registry updated 2026-06-17·Phase 3·ALXN
Active, not recruiting

Primary endpoint: A Hierarchical Combination of Time to All-cause Mortality and Frequency of Cardiovascular Hospitalizations (CVHs) Analyzed by Win Ratio

InterventionalRandomizedquadruple281 targetStarted 2020-11Completion 2027-0450 sites · Australia, Austria, Belgium, Brazil…Alexion Pharmaceuticals, Inc.

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis

NCT04504825Registry updated 2026-03-17·Phase 3·ALXN

Primary endpoint: A hierarchical combination of Time to All-cause Mortality and Frequency of Cardiovascular hospitalizations

InterventionalRandomizedquadruple125 targetStarted 2020-08Completion 2027-1050 sites · Australia, Austria, Belgium, Brazil…Alexion Pharmaceuticals, Inc.